Navigation Links
Raven Announces Phase 1 Clinical Trial Results of RAV12 Therapeutic Antibody for Treatment of Adenocarcinomas
Date:11/19/2007

on day 42.

Study Results

RAV12 was moderately well-tolerated with fractionated dosing that allowed delivery of an "effective dose" (i.e. 1.5 mg/kg total dose over one week time) as 0.75 mg/kg twice weekly. The two primary side effects observed were Infusion-associated abdominal discomfort and diarrhea, and elevated liver function tests. Both side effects appear related to CMax as they tended to appear early on after dosing and tended to resolve rapidly after dosing, and were ameliorated by fractionated dosing.

Treatment with RAV12 demonstrated preliminary evidence of anti-tumor activity. One patient with refractory colorectal cancer experienced a partial remission with time to progression exceeding 8 months and one patient with advanced pancreatic cancer had a > 50% reduction in the relevant tumor marker, CA19-9 and experienced disease stability for more than five months.

As a result of these findings, future development of RAV12 both as single agent and in combination with chemotherapy is planned for 2008. The recommended dose and schedule for Phase 2 clinical study of RAV12 is 0.75 mg/kg twice weekly.

About RAV12

RAV12 is a novel, chimeric monoclonal antibody which is directed against a primate-specific glycotope (sugar structure) that is widely displayed on the surfaces of tumor cells, particularly those of gastrointestinal origin (gastroesophageal, pancreatic, colorectal cancers). Preclinical studies have demonstrated that RAV12 may kill tumor cells in a number of ways: first, the antibody is directly cytotoxic to a human colon cancer cell line in vitro through induction of oncotic cell death, a form of cell death characterized by cell and organelle swelling and loss of membrane integrity; second, the antibody mediates antibody-dependent cellular cytotoxicity; third, the antibody mediates complement dependent cell killing; and finally, the antibody alters cellular signaling required for cell survival. RAV12 is highly efficacio
'/>"/>

SOURCE Raven biotechnologies, inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Cadence Pharmaceuticals Completes Enrollment of Pivotal Phase III Trial for Intravenous Acetaminophen Ahead of Schedule
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
4. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
5. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
8. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
9. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
10. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
11. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2015)... June 30, 2015 Today, UBM China, a ... agreement with Chengdu Tianyi Exhibition Co., Ltd. to jointly ... is to be held concurrently with CWMEE 2016. ... healthcare exhibition family, following MEDTEC China and DENTECH China, ... in west China. It,s also another concrete cooperative project ...
(Date:6/30/2015)... und KOPENHAGEN, Dänemark, 30. Juni 2015 /PRNewswire/ ... Weltmarktführer der klinischen und kommerziellen Produktion von ... heute bekannt, dass das Unternehmen im Rahmen ... der nordamerikanischen Produktionsanlage in Bothell, ... Einweg-Anlage Bioreactor 6Pack™ komplettiert hat. Die Konfiguration ...
(Date:6/30/2015)... 2015  EnteroMedics Inc. (NASDAQ: ETRM ), a ... to treat obesity, metabolic diseases, and other gastrointestinal disorders, ... of 40,229,886 units. Each unit consists of one share ... to purchase one share of common stock, and 0.50 ... of common stock, at a purchase price of $0.87 ...
Breaking Medicine Technology:UBM Joins Chengdu Tianyi to Hold CWMEE 2016 2UBM Joins Chengdu Tianyi to Hold CWMEE 2016 3CMC Biologics baut GMP-Produktionskapazität in den USA aus 2CMC Biologics baut GMP-Produktionskapazität in den USA aus 3EnteroMedics Inc. Announces Pricing of $35.0 Million Public Offering of Common Stock and Warrants 2EnteroMedics Inc. Announces Pricing of $35.0 Million Public Offering of Common Stock and Warrants 3
... Inc. (Nasdaq: OPTR ) today announced it expects ... after the NASDAQ Global Market closes on Thursday, March 10, ... that day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific ... fourth quarter and full year 2010, as well as provide ...
... CRANBURY, N.J., March 3, 2011 Palatin Technologies, Inc. (NYSE ... Food and Drug Administration (FDA) has cleared Palatin,s request to ... New Drug (IND) application using a subcutaneously administered formulation of ... acute exacerbations of asthma. "We are excited ...
Cached Medicine Technology:Optimer Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2010 Financial Results 2FDA Clears Palatin Technologies' IND Filing to Commence Clinical Studies for Asthma 2
(Date:6/30/2015)... (PRWEB) , ... June 30, 2015 , ... Ticket Down is a reputable source of ... native of Detroit, MI, Kid Rock, is hitting the road again this summer in what ... and hip hop superstar kicked off his summer tour this year at the XFINITY Theatre ...
(Date:6/30/2015)... ... June 30, 2015 , ... The ... launched a ‘responsive design’ website to inform potential sinus surgery patients about ear, ... The website includes information about a wide variety of ENT issues including hearing ...
(Date:6/30/2015)... ... June 30, 2015 , ... ADVOCATE, the premier provider of ... Mann, CPC, RCC, ROCC, Coding Documentation and Education Manager, was honored at the ... for her contribution to the RBMA Coding Subcommittee. , Ms. Mann served ...
(Date:6/30/2015)... ... June 30, 2015 , ... Today, Grand Terrace Health Care ... Care Center.” Each year, Medicare ranks care centers around the country in an ... their needs. Grand Terrace prides itself on quality in each of Medicare’s evaluation ...
(Date:6/30/2015)... ... 30, 2015 , ... According to a June 15th report from ... how sensory stimuli can be used to “decrease children’s anxiety and negative responses during ... autism, will compare patient experience in a “typical dental environment” with one that provides ...
Breaking Medicine News(10 mins):Health News:Cheap Kid Rock Tickets at the DTE Energy Music Theatre in Clarkston: Ticket Down Has Slashed Prices On All Kid Rock Tickets at DTE in the Detroit Metro Area 2Health News:Clear Lake Medical Center ENT Launches ‘Responsive Design’ Website 2Health News:Clear Lake Medical Center ENT Launches ‘Responsive Design’ Website 3Health News:ADVOCATE’s Debby Mann Honored With Special Recognition Award 2Health News:Grand Terrace Health Care Center Announces Five-Star Rating in YouTube Video 2Health News:New Study Aims to Determine if Sensory Stimuli can Ease Dental Anxiety in Children, Notes Medical Center Dental Care 2Health News:New Study Aims to Determine if Sensory Stimuli can Ease Dental Anxiety in Children, Notes Medical Center Dental Care 3
... , MONDAY, April 23 (HealthDay News) -- Hispanic people ... black people with the disease, according to a new study. ... due to genetic factors or environmental advantages, such as lower ... examined diagnosis and survival data on cancer patients from a ...
... Army Medical Center (BAMC)/San Antonio Military Medical Center (SAMMC) will ... that he hopes will extend the shelf life of and ... Maj. Jean M. Muderhwa is slated to present at 12:25 ... on a microemulsion he developed and that has been found ...
... April 20 (HealthDay News) -- Searching for a favorite song ... distracted driving, researchers say. About 90 percent of new ... makers of aftermarket MP3 controllers make devices claimed to decrease ... according to the new study. The study included 50 ...
... April 2012): Widespread screening of children in poorer countries is ... rheumatic heart disease (RHD) in patients that would likely have ... carried out in Fiji and Uganda presented today at the ... control programmes can help to identify patients before they progress ...
... (HealthDay News) -- The breed of dog a person chooses ... new study suggests. The online survey of 1,000 ... England, found certain personality traits, such as extroversion, agreeableness and ... is to be presented Friday at the British Psychological Society ...
... studies analyzing treatment decisions in late-stage amyotrophic lateral sclerosis ... the duration and quality of life in this progressively ... Medicine at the University of Pennsylvania found that waiting ... in not living long enough to experience the benefits. ...
Cached Medicine News:Health News:Hispanics Seem to Have Better Odds of Lung Cancer Survival 2Health News:Army researcher develops potential vaccine carrier 2Health News:Army researcher develops potential vaccine carrier 3Health News:Long MP3 Playlists Lead to Distracted Drivers 2Health News:Screening programs detect cases of undiagnosed rheumatic heart disease in low-resource countries 2Health News:Could Your Personality Be Reflected in Your Pooch? 2Health News:ALS patients differ on treatment choices in later phases of disease 2
The Maxi-Therm® lite hyper-hypothermia water blankets from Cincinnati Sub-Zero take conductive warming and cooling therapy to a new, softer level. These blankets are soft, lightweight, and remai...
The Neuro-Cool™ System provides pain relief by combining a head wrap with a cold therapy unit for effective migraine treatment....
... The BCI® Oximetry Data Management Program ... for use with the FingerPrint® Sleep ... Smiths Medical PM, Inc. catalog #3389 ... collected during sleep screening, oxygen therapy ...
... The ImmunoWELL Mumps IgG Test ... the qualitative detection of IgG ... are used as an aid ... Immune status may be determined ...
Medicine Products: